Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma

被引:84
作者
Perea, S
Pennick, GJ
Modak, A
Fothergill, AW
Sutton, DA
Sheehan, DJ
Rinaldi, MG
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA
[2] S Texas Vet Hlth Care Syst, Audir Murphy Div, San Antonio, TX USA
[3] Pfizer Inc, Pfizer Pharmaceut Grp, New York, NY USA
关键词
D O I
10.1128/AAC.44.5.1209-1213.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
A new selective high-performance liquid chromatography (HPLC) method with UV detection for the determination of the investigational triazole voriconazole in human plasma by using acetonitrile precipitation followed by reverse-phase HPLC on a C-18 column was compared with a simple agar well diffusion bioassay method with Candida kefyr ATCC 46764 as the assay organism. Pooled plasma was used to prepare standard and control samples for both methods. The results of analyses with spiked serum samples (run as unknowns) were concordant by the bioassay and HPLC methods, with expected values being obtained. HPLC demonstrated an improved precision (3.47 versus 12.12%) and accuracy (0.81 versus 1.28%) compared to those of the bioassay method. The range of linearity obtained by both methods (from 0.2 to 10 mu g/ml for HPLC and from 0.25 to 20 mu g/ml for the bioassay) includes the range of concentrations of voriconazole (from 1.2 to 4.7 mu g/ml) which are considered clinically relevant. Although either methodology could be used for the monitoring of patient therapy, the smaller variability observed with HPLC compared to that observed with the bioassay favors the use of HPLC for pharmacokinetic studies.
引用
收藏
页码:1209 / 1213
页数:5
相关论文
共 21 条
[1]  
BAILEY EM, 1990, PHARMACOTHERAPY, V10, P146
[2]   In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949
[3]   Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species [J].
Belanger, P ;
Nast, CC ;
Fratti, R ;
Sanati, H ;
Ghannoum, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1840-1842
[4]   Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery [J].
Caillot, D ;
Casasnovas, O ;
Bernard, A ;
Couaillier, JF ;
Durand, C ;
Cuisenier, B ;
Solary, E ;
Piard, F ;
Petrella, T ;
Bonnin, A ;
Couillault, G ;
Dumas, M ;
Guy, H .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :139-147
[5]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[6]   Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis [J].
George, D ;
Miniter, P ;
Andriole, VT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) :86-91
[7]   Use of voriconazole in treatment of Scedosporium apiospermum infection:: Case report [J].
Girmenia, C ;
Luzi, G ;
Monaco, M ;
Martino, P .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (05) :1436-1438
[8]   DISCREPANCIES IN BIOASSAY AND CHROMATOGRAPHY DETERMINATIONS EXPLAINED BY METABOLISM OF ITRACONAZOLE TO HYDROXYITRACONAZOLE - STUDIES OF INTERPATIENT VARIATIONS IN CONCENTRATIONS [J].
HOSTETLER, JS ;
HEYKANTS, J ;
CLEMONS, KV ;
WOESTENBORGHS, R ;
HANSON, LH ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (10) :2224-2227
[9]   In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].
Marco, F ;
Pfaller, MA ;
Messer, S ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163
[10]   Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs [J].
Martin, MV ;
Yates, J ;
Hitchcock, CA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :13-16